Adverse Experience Reporting for Licensed Biological Products; and General Records

Forms and Documents

Forms and supporting documents for this ICR

Document	Type	Status	Availability

No forms / supporting documents in this ICR. Check IC Document Collections.

IC Document Collections

Information collection document groups

IC ID	Collection	Type	Status	Form
5875	Adverse Experience Reporting for Licensed Biological Products; and General Records	Form	Migrated

ICR Details

OMB Control No: 0910-0308	ICR Reference No: 200012-0910-005
Status: Historical Active	Previous ICR Reference No: 199903-0910-001
Agency/Subagency: HHS/FDA	Agency Tracking No:
Title: Adverse Experience Reporting for Licensed Biological Products; and General Records
Type of Information Collection: Extension without change of a currently approved collection	Common Form ICR:  No
Type of Review Request: Regular
OIRA Conclusion Action: Approved without change	Conclusion Date: 04/13/2001
	Date Received in OIRA: 12/29/2000
Terms of Clearance: FDA shall continue to work with the regulated community to seek ways to integrate and streamline its adverse event reporting systems to the extent that such changes can improve and simplify reporting. FDA shall take care to work closely with interested parties who would be affected by any changes and will subject any redesigns to public comment prior to OMB submission.

table that charts list comparision

	Inventory as of this Action	Requested	Previously Approved
Expiration Date	05/31/2003	05/31/2003	05/31/2001
Responses	17,406	0	3,212
Time Burden (Hours)	268,803	0	342,132
Cost Burden (Dollars)	0	0	0

---

Abstract: The AER requirements enable FDA to take actions necessary for the protection of the public health in response to reports of adverse experiences related to licensed biological products. The recordkeeping requirements serve preventative and remedial purposes by requesting accountability and traceability in each step from the manufacture to distribution and recall of products and by enabling FDA to perform meaningful inspections. Respondents to the collection of information are manufacturers of biological products.

---

Authorizing Statute(s): None

Citations for New Statutory Requirements: None

---

Associated Rulemaking Information
RIN:	Stage of Rulemaking:	Federal Register Citation:	Date:

---

Federal Register Notices & Comments

Did the Agency receive public comments on this ICR? No

---

Number of Information Collection (IC) in this ICR: 1

table that charts list of burden

IC Title	Form No.	Form Name
Adverse Experience Reporting for Licensed Biological Products; and General Records	N/A

---

ICR Summary of Burden

table that charts list of burden

	Total Approved	Previously Approved	Change Due to New Statute	Change Due to Agency Discretion	Change Due to Adjustment in Estimate	Change Due to Potential Violation of the PRA
Annual Number of Responses	17,406	3,212	0	14,194	0	0
Annual Time Burden (Hours)	268,803	342,132	0	-73,329	0	0
Annual Cost Burden (Dollars)	0	0	0	0	0	0

Burden increases because of Program Change due to Agency Discretion: No

Burden Increase Due to:

Burden decreases because of Program Change due to Agency Discretion: Yes

Burden Reduction Due to:

Short Statement:

---

Annual Cost to Federal Government: $0

Does this IC contain surveys, censuses, or employ statistical methods? No

Is the Supporting Statement intended to be a Privacy Impact Assessment required by the E-Government Act of 2002? No

Is this ICR related to the Affordable Care Act [Pub. L. 111-148 & 111-152]? Uncollected

Is this ICR related to the Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]? Uncollected

Is this ICR related to the American Recovery and Reinvestment Act of 2009 (ARRA)? Uncollected

Is this ICR related to the Pandemic Response? Uncollected

---

Common Form ICR:  No

---

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).

The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:

(a) It is necessary for the proper performance of agency functions;

(b) It avoids unnecessary duplication;

(c) It reduces burden on small entities;

(d) It uses plain, coherent, and unambiguous language that is understandable to respondents;

(e) Its implementation will be consistent and compatible with current reporting and recordkeeping practices;

(f) It indicates the retention periods for recordkeeping requirements;

(g) It informs respondents of the information called for under 5 CFR 1320.8 (b)(3) about:

(i) Why the information is being collected;

(ii) Use of information;

(iii) Burden estimate;

(iv) Nature of response (voluntary, required for a benefit, or mandatory);

(v) Nature and extent of confidentiality; and

(vi) Need to display currently valid OMB control number;

(h) It was developed by an office that has planned and allocated resources for the efficient and effective management and use of the information to be collected.

(i) It uses effective and efficient statistical survey methodology (if applicable); and

(j) It makes appropriate use of information technology.

If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.

Certification Date: 12/29/2000

---